The Future of Synthetic Biology
While BiPlastiq presently services the ecosystem for Bio-Fabrication, our executive team has a long-term vision that encompasses the emerging market for Regenerative Therapeutics —a field, which will quickly supplant traditional forms of medicine.
Image a world where bioreactors produce tissue replacements in hours rather than weeks, and where Regenerative Therapies heal patients in weeks rather than months.
Integrating BiPlastiq into such therapeutic applications will profoundly enhance their efficiency and cost-effectiveness. This is because BiPlastiq enhances the very cells on which Synthetic Biology depends, making energy instantaneously available to cells during their most metabolically-intensive tasks.
This is the Future of Synthetic Biology...
And BiPlastiq will not only revolutionize today's advancements, but it will also evolve to meet the demands of tomorrow's developers. Let us explore how BiPlastiq might enhance the future of Regenerative Therapeutics...
Therapeutic cloning utilizes cell-samples from a patient (or donor) to produce replacements for damaged tissues and organs. Eventually, BiPlastiq will enhance the cells contained within such replacement-constructs, allowing bioreactors to produce them at an accelerated rate (and at lower cost). And all these benefits will exist without fear of rejection, since the replacements will be derived from the patient's own cells.
Regenerative therapies often engineer cells into treatment carriers. In this context, Cellular Therapy is a regenerative strategy that treats disease (or injury) by introducing engineered cells into afflicted tissues. This therapy requires the harvesting of pluripotent cells from a patient (or donor). Once engineered to treat a specific ailment, these cells are then combined with growth factors to form a serum for the treatment. Upon implantation, these cells will integrate into fatigued tissues, dividing into the cellular replacements needed for recovery.
BiPlastiq's features will be genetically engineered into the harvested cells, providing both the cell and their progeny with metabolic enhancements. Once activated by an advance form of Light Therapy, BiPlastiq's modifications will profoundly enhance the therapeutic's effectiveness, dramatically increasing the energy available to these pluripotent cells during the metabolically intensive tasks involved in regeneration.
Remarkably, BiPlastiq's most profound impact could be in the field of Senescence, which studies the deterioration of tissues resulting from age. Recent studies suggest that this deterioration is somewhat attributable to the attrition (or loss) of cells. Luckily, pluripotent cells continually combat the ravages of aging by repopulating our bodies with cellular replacements. Yet as we age, the population of pluripotent cells within our bodies dwindles, ultimately reducing their regenerative capabilities. Our researchers believe that by promoting the longevity and versatility of these cells, BiPlastiq's enhancements might one day aid in slowing (and even reversing) the effects of senescence.